SANTEN-PHARMACEUTICAL
26.7.2021 09:02:06 CEST | Business Wire | Press release
Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services.
Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We take the adoption of this resolution as an opportunity to further enhance our policy and advocacy activities with the IAPB.
“The eye health sector has believed for a long time that quality eye care is critical to the world achieving the Sustainable Development Goals” said Peter Holland, CEO of IAPB. “IAPB and its members are committed to supporting governments to implement this resolution and ensure that no one is left behind”.
To support the implementation of this resolution, Santen and the IAPB will work together on a number of initiatives as part of their ongoing strategic partnership , including:
- Partnership with national governments and supranational stakeholders to establish an effective monitoring system and encourage the inclusion of eye health in voluntary national reporting on the Sustainable Development Goals (SDGs).
- Coordination of an advocacy and public affairs strategy to lobby for the inclusion of two eye health targets in the next review of the SDGs by the UN Inter-Agency Expert Group in 2025.
Today, 1.1 billion people are living with preventable sight loss due to a lack of access to basic eye care services. With appropriate allocation of resources and investment for the early detection and treatment of eye conditions, including disease awareness campaigns and regular eye tests, sight can be protected.1 Vision loss can have a significant detrimental impact on quality of life (QOL), including depression, discomfort and social isolation. Improving access to eye care services therefore, has the potential to improve the QOL for millions of people.2 Additionally, sight loss is calculated to cost the global economy $411bn in productivity each year, showing it has tremendous economic consequences3 . Eye health is directly linked to more than half of the sustainable development goals (SDGs), including eliminating poverty and hunger, improving education, and gender equality4 . Therefore, a “whole of government approach” to eye care and strengthened collaboration between stakeholders is necessary to ensure the people living with preventable sight loss receive access to support and treatment.
“The adoption of UN resolution on eye health represents a major leap towards the realization of our WORLD VISION (Happiness with Vision)” said Shigeo Taniuchi, President & CEO of Santen, “There is ample evidence that eye health is a global development issue. About 90% of preventable vision loss occurs in low and middle income countries, of which 55% affects women and girls. People, in general, receive 80% of information visually and eye disease tend to be chronic, affecting patients’ quality of life. As a specialized company dedicated to ophthalmology, we are committed to promoting international efforts on eye health and contributing to the realization of the SDGs. Supporting the implementation of this resolution is a crucial step towards facilitating access to eye care services and reducing the loss of social and economic opportunities for people around the world due to eye conditions”.
References:
- International Agency for the Prevention of Blindness (IAPB). Vision Atlas. Available here: https://www.iapb.org/learn/vision-atlas
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
- Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
About Santen
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.
Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.
With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (www.santen.com
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005246/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
